Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604972 | 0.98 | ELANE (0.73) | ELANEKDM4ENPSR1 | |
| Acetic Acid SCHEMBL1603917 | 0.97 | ELANE (0.69) | ELANE | |
| Iodide SCHEMBL1603664 | 0.97 | ELANE (0.72) | ELANE | |
| SCHEMBL1604046 | 0.95 | ELANE (0.75) | ELANEKDM4ENPSR1 | |
| Acetic Acid SCHEMBL1604007 | 0.93 | ELANE (0.72) | ELANEKDM4ENPSR1 | |
| SCHEMBL14922184 | 0.90 | ELANE (0.80) | ELANEKDM4ENPSR1 | |
| SCHEMBL6882889 | 0.89 | ELANE (0.59) | ELANEKDM4ENPSR1 | |
| SCHEMBL14922185 | 0.89 | ELANE (0.81) | ELANEKDM4ENPSR1 | |
| SCHEMBL1604295 | 0.89 | ELANE (0.73) | ELANE | |
| SCHEMBL1604290 | 0.89 | ELANE (0.77) | ELANEKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | claimed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436024-B2 | 2-pyridone compounds | ASTRAZENECA AB (GB) | 2013-05-07 | — | — | US | disclosed |
| WO-2011039528-A1 | 2-PYRIDONE COMPOUNDS USED AS INHIBITORS OF NEUTROPHIL ELASTASE | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | WO | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082155-A1 | Novel 2-Pyridone Compounds | ASTRAZENECA AB (SE) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082155-A1 | Novel 2-Pyridone Compounds | SERPINB1, ELANE, EPX | ELANE 2/4885KDM4E 1513/4885NPSR1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.